left-arrow

blog

right-arrow
word-image-8150-1

AOD-9604 vs Tesamorelin vs MOTS-c: Which Peptide Is Best for Fat Loss?

Published: February 26, 2026

Quick Summary

If you only remember one thing, make it this: tesamorelin is the only one of the three with FDA approval and solid human trials, and what it does well is shrink the deep belly fat around your organs, not drop the number on the scale. AOD-9604 is a fragment of growth hormone that was supposed to burn stored fat without touching IGF-1, but in the bigger human trials it didn’t do better than placebo, and it was never approved. MOTS-c is made by your own mitochondria and looks promising for insulin sensitivity in mice, though the human research is still thin, so which one makes sense really depends on your labs and what you’re trying to change.

If you’ve been reading up on AOD-9604 vs tesamorelin, you’ve probably noticed that a lot of websites talk about them as if they were two brands of the same fat burner. They really aren’t. These two peptide therapy options work in different parts of the body, they have very different amounts of research behind them, and only one of them has ever been approved by the FDA for anything at all.

MOTS-c tends to get mentioned in the same breath, so we’ve included it here too. What follows is our plain-language take on what each of these peptides does, what the studies actually found, and who each one might make sense for.

For what it’s worth, at InShapeMD in San Angelo nobody starts a peptide based on a blog post, this one included. Every plan starts with comprehensive labs and an appointment with an FNP, because the right choice depends on your body, your history, and what you’re hoping to change.

AOD-9604 vs Tesamorelin: Key Differences

If you want the quick comparison before the details, it really comes down to how each one works, where it acts, and who it tends to suit. Each of these gets more room in the sections further down.

Start with how they work. As a small, lab-made piece of the human growth hormone molecule (amino acids 177-191), AOD-9604 acts on fat cells themselves and was meant to speed up fat breakdown, and in studies it barely moved IGF-1 or blood sugar. Tesamorelin is a lab-made version of GHRH, the hormone your brain uses to tell the pituitary to release growth hormone, so it raises your own growth hormone and IGF-1, and it can nudge blood sugar up, which is why both get checked.

Then there’s where they act. AOD-9604 was aimed at stored fat in general, including the stubborn spots, while tesamorelin mainly shrinks visceral fat, the deep fat that sits around your organs. The evidence is lopsided too: the bigger human trials of AOD-9604 didn’t beat placebo for weight loss and it was never approved, whereas tesamorelin has randomized trials behind it and is approved as Egrifta WR for abdominal fat in adults with HIV-associated lipodystrophy, which makes any other use off-label.

As for who each one suits, AOD-9604 usually comes up for someone who wants a little fat-focused help without raising growth hormone and is fine with modest expectations. Tesamorelin makes more sense for someone whose main worry is belly fat and who doesn’t mind regular glucose and IGF-1 checks.

So the short answer is that tesamorelin has the better evidence but a narrow job, while AOD-9604 is gentler on your hormones but hasn’t shown much proof that it takes fat off people.

 An image of an elderly man exercising

AOD-9604: A Growth Hormone Fragment Aimed at Stored Fat

AOD-9604 started out as an idea that made a lot of sense on paper. Growth hormone helps the body break down fat, but it also affects growth, blood sugar, and IGF-1, which you don’t necessarily want. So researchers took the small piece of the molecule that seemed to carry the fat-burning signal, added one amino acid to keep it stable, and made it in a lab on its own.

In early lab and animal work it did roughly what they’d hoped. It sped up lipolysis, which is the breakdown of stored fat, and slowed lipogenesis, the building of new fat. That’s why, back in the early 2000s, it was being developed as an obesity drug.

The trouble came with the bigger human trials. The company behind it couldn’t show meaningful weight loss compared with a placebo, and development as an obesity treatment was dropped. The safety results in those trials were reassuring for the most part, but there still isn’t much long-term data.

It’s also worth knowing that AOD-9604 isn’t FDA-approved, and it wasn’t one of the six peptides covered by the federal government’s October 2026 interim compounding policy. So before you get your heart set on it, ask us what’s actually available and where it would come from. There’s more detail on our AOD 9604 page.

Who AOD-9604 May Suit

When AOD-9604 does come up in a consultation, it’s usually with adults who want a bit of extra help with fat that hasn’t budged with diet and exercise, and who would rather leave their growth hormone and IGF-1 alone. Even then, we think of it as one small part of a bigger plan rather than the plan itself.

Tesamorelin: The Most Studied Option for Visceral Fat

Tesamorelin is a copy of the hormone your brain uses to tell the pituitary gland to release growth hormone. So instead of injecting growth hormone directly, you’re turning up your body’s own supply. IGF-1 rises as a result, and the way your body stores and uses fat starts to shift.

Of the three peptides in this article, it’s the only one the FDA has approved. The current version is sold as Egrifta WR, and its approval is narrow: it’s for reducing excess abdominal fat in adults with HIV who have lipodystrophy, according to its FDA prescribing information. In the trials behind that approval, it reduced visceral fat, which is the deep fat you can’t pinch and the kind most closely tied to heart disease and diabetes. Those trials measured the change after 26 weeks, so it’s a treatment you judge over months, not days.

Here’s the part that tends to surprise people. The label says plainly that it isn’t meant for weight loss, because total body weight stayed about the same in the studies. What changed was where the fat was sitting. So if you’re hoping to drop twenty pounds, this probably isn’t the right tool, but if your waistline and your bloodwork are what worry you, it may be worth talking about.

Outside the approved group, tesamorelin is used off-label. That isn’t unusual in medicine, but it does mean your provider should be able to explain why it fits you, roughly how long it takes, and what will be monitored along the way.

Tesamorelin Side Effects and Monitoring

The side effects people report most often are joint aches, sore muscles, some swelling in the hands or feet, and redness or itching where they inject. Blood sugar can creep up too, which is why we’d check glucose and IGF-1 before you start and again once you’re a few weeks in.

It isn’t an option if you have active cancer, certain pituitary problems, or you’re pregnant. You can read how we handle tesamorelin injections at InShapeMD if you’d like the practical details.

An image of a man exercising

MOTS-c: A Mitochondrial Peptide for Metabolic Health

MOTS-c is a different kind of peptide altogether. It’s a short chain of 16 amino acids that your own mitochondria make, using instructions stored in mitochondrial DNA rather than the DNA in the rest of the cell. Your body makes more of it when you exercise, and levels tend to fall as you get older.

In lab and mouse studies, MOTS-c switched on something called AMPK, which works a bit like the cell’s fuel gauge. When that happened, insulin sensitivity improved and muscle got better at pulling glucose out of the blood. Mice eating a high-fat diet also put on less weight, as described in a review indexed by the National Library of Medicine.

What we don’t have yet is much human data. MOTS-c isn’t FDA-approved, although an FDA advisory committee voted in July 2026 to recommend allowing pharmacies to compound it. Then, on October 28, 2026, HHS issued a temporary interim policy that lets state-licensed pharmacies compound MOTS-c with a prescription while the FDA finishes its formal rule. That policy can be pulled back if safety concerns come up, and it isn’t the same thing as approval.

Because it works on how your cells use fuel rather than on fat stores directly, MOTS-c usually comes up in conversations about metabolic flexibility, energy, and insulin resistance. Our MOTS-c peptide therapy page goes into more detail.

How MOTS-c Compares to AOD-9604 and Tesamorelin

AOD-9604 and tesamorelin are both aimed at fat, one by acting on fat cells and the other by working through growth hormone. MOTS-c works one step further back, on how easily your cells switch between burning sugar and burning fat.

That’s why some providers see it as something that could sit alongside the other two rather than compete with them, especially for patients dealing with insulin resistance. If mitochondrial health is what interests you most, our guide to NAD+ vs MOTS-c covers it in more depth.

Which Peptide Is Right for You?

There isn’t one peptide that’s best for everybody. The right choice depends on where you carry fat, what your labs show, and how much monitoring you’re comfortable with, so it helps to think of what follows as things to bring up at your visit rather than a way to pick for yourself.

If deep belly fat is your main concern, tesamorelin has the best evidence for reducing visceral fat, as long as glucose and IGF-1 are watched. If you’d rather not raise your growth hormone or IGF-1 at all, AOD-9604 may come up, with the understanding that the evidence for it is weak. If insulin resistance or a slowing metabolism seems to be part of the problem, MOTS-c might be worth discussing as metabolic support, keeping in mind that human research is still early. And if what you really need is significant overall weight loss, a GLP-1 medication like semaglutide has far more evidence behind it than any of these three peptides.

We’ll also take your age, the medications you already take, and your health history into account. Conditions like diabetes, a past cancer, or pituitary problems can rule some of these options out.

Can These Peptides Be Combined?

Some clinics do combine them, on the reasoning that they act through different pathways and might add up. That may turn out to be true, but nobody has published a human trial of AOD-9604, tesamorelin, and MOTS-c used together, so any combination needs to be tailored to you and watched closely.

An image of a man working out

Peptides Work Best Alongside Healthy Habits

No peptide gets around the basics. Eating enough protein, doing strength and resistance training, sleeping properly, and keeping stress in check all play a part in whether your body holds on to fat or lets it go.

Medical supervision matters just as much. Getting the dose right, repeating labs, and checking in often are how side effects get caught early and how a plan gets adjusted as your body changes.

Start Your Peptide Consultation at InShapeMD

When you come in, we build your plan around your labs, your goals, and your schedule, and you’ll have 1-on-1 support from our team the whole way through. We’ll go over the evidence for each option with you, including which ones are FDA-approved and which aren’t, so whatever you decide, you’re deciding with the full picture.

You can explore our peptide therapy options or book your consultation whenever you’re ready, or give us a call at (325) 227-4981. Consultations are free, and no insurance is required.

FAQs

Is AOD-9604 better than tesamorelin for fat loss?

Based on the research we have, no, at least when the goal is shrinking belly fat, and the easiest way to see which fits you is to bring your recent labs and goals to a consultation. If you’d rather keep your IGF-1 where it is, AOD-9604 is still something we can talk through, as long as you go in expecting modest results. Which one fits you is something we’d work out together at your visit.

Can you combine AOD-9604 and tesamorelin?

Some providers do, but it’s usually something to consider only after you’ve given one of them a fair try on its own. Since the pairing hasn’t been studied in people, ask your provider what they expect it to add before you agree to it. If you do go ahead, plan on baseline labs, a recheck of blood sugar and IGF-1 a few weeks in, and regular check-ins so the plan can be changed or stopped.

What is the difference between AOD-9604 and MOTS-c?

AOD-9604 is a fragment of growth hormone that was designed to break down stored fat. MOTS-c is made by your mitochondria and affects how your cells use sugar and fat for fuel, mainly by switching on AMPK. In other words, one is about breaking fat down and the other is about insulin sensitivity and metabolic flexibility, and neither has FDA approval or much human research yet.

How long does it take for AOD-9604 to work?

There isn’t an established timeline, because AOD-9604 has no approved dosing schedule and very little human research. Clinics that use it usually reassess after several weeks of consistent use alongside changes to diet and exercise, and when results show up they tend to be gradual. It’s a good idea to agree on check-in dates with your provider at the start so you can decide together whether to keep going.

Which peptide is best for visceral fat reduction?

Tesamorelin is the one with the evidence here. It’s the only peptide in this comparison with randomized trials showing less visceral fat, the deep belly fat linked to metabolic disease, and it’s FDA-approved for that in adults with HIV-associated lipodystrophy. For anyone outside that group it’s off-label, and blood sugar and IGF-1 need to be monitored.

brenda

MEDICALLY REVIEWED BY

Brenda Kaye Harrison, MSN, APRN, FNP

Nurse Practitioner · Weight Management & Hormone Therapy · 15 years of experience as an NP

We are passionate about empowering people in their weight loss journey. Experience real transformation with InShapeMD in San Angelo, Texas. Schedule a consultation to get started today.

GET EXPERT HELP

We are passionate about empowering people in their weight loss journey. Experience real transformation with InShapeMD in San Angelo, Texas. Schedule a consultation to get started today.

Back to top